QLT Inc. (TSE:QLT) Files An 8-K Other Events

QLT Inc. (TSE:QLT) Files An 8-K Other Events

Item 8.01. Other Events.

QLT Inc. (QLT) is filing this Current Report on
Form8-K solely for the purposes of updating the pro forma
financial information of QLT and Aegerion Pharmaceuticals,Inc.
(Aegerion) relating to the merger between
Aegerion and an indirect wholly-owned subsidiary of QLT. The
unaudited pro forma condensed combined financial statements, and
the accompanying notes, of QLT and Aegerion as of and for the
nine months ended September30, 2016 and the year ended
December31, 2015 (the Pro Forma Financial
Statements) are attached hereto as Exhibit99.1. The Pro
Forma Financial Statements supplement, update and supersede the
unaudited pro forma condensed combined financial statements, and
the accompanying notes, of QLT and Aegerion as of and for the six
months ended June30, 2016 and the year ended December31, 2015
contained in the definitive joint proxy statement/prospectus that
forms part of the registration statement on FormS-4 (the
Registration Statement) filed with the U.S.
Securities and Exchange Commission by QLT on October6, 2016 and
mailed to shareholders of QLT and stockholders of Aegerion on or
about October7, 2016, and should be read in conjunction therewith
and the other financial statements included or incorporated in
the Registration Statement.

The Pro Forma Financial Statements attached hereto as Exhibit99.1
are incorporated herein by reference.

About QLT Inc. (TSE:QLT)
QLT Inc. is a biotechnology company. The Company is focused on the development and commercialization of ocular products. The Company’s operations consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal. The Company is developing QLT091001 for the treatment of IRD caused by RPE65 and LRAT gene mutations, which indication includes Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). It has completed a Phase Ib clinical proof of concept study and a follow-up retreatment study in LCA and RP patients with autosomal recessive mutations in RPE65 or LRAT, and a Phase 1b study in RP patients with autosomal dominant mutations in RPE65. QLT Inc. (TSE:QLT) Recent Trading Information
QLT Inc. (TSE:QLT) closed its last trading session down -0.03 at 2.49 with 0 shares trading hands.